Slide background
Slide background




Safe design and operation of on site generation of oxygen 93% for medical use

ID 1668 | | Visite: 5370 | Documenti Chemicals EntiPermalink: https://www.certifico.com/id/1668



Safe design and operation of on site generation of oxygen 93% for medical use

Oxygen for medicinal use is a prime requirement for all healthcare facilities for both the treatment of patients with respiratory disease and for providing additional oxygen to patients being treated within the facility.

For those hospitals and clinics, where the demand is higher, oxygen is normally distributed throughout the facility using a medical gas pipeline system.

The design requirements for the supply source used to supply medical oxygen to the pipeline system are detailed in the standard, EN ISO 7396-1 Medical gas pipeline systems; Pipeline systems for compressed medical gases and vacuum.

Two different products are included in the standard:

- Medicinal oxygen supplied from liquid oxygen vessels and/or gaseous oxygen cylinders; and
- Oxygen 93 manufactured on-site within the healthcare facility, using an oxygen concentrator unit.

Medicinal oxygen supplied either in cylinders or as a cryogenic liquid, is required to be manufactured by an approved supplier with a manufacturers licence (to demonstrate compliance with guidelines detailed in the European Commission’s Guide to Good Manufacturing Practice (GMP))

Within the European Union, the supplier of medical oxygen is required to hold a marketing authorisation in accordance with Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, detailing the clinical indications and contraindications and specific warnings for the safe use of the product.

The specification of this medical oxygen is detailed in the European Pharmacopoeia monograph for medical oxygen, which specifies a minimum purity of 99.5% oxygen.

The quality, safety and efficacy of the medical oxygen are ensured by the medical gas supplier through a quality management system under the responsibility of a qualified person.

Oxygen 93 can be manufactured on-site within the healthcare facility, under the responsibility of the healthcare facility pharmacist, using an oxygen 93 supply system and meeting the appropriate and specific quality and safety criteria for medicinal products prepared in Pharmacies (see Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Guide PE010-4 Guideline to good practices for the preparation of medicinal products in healthcare establishment).

Oxygen 93 is not being ‘put on the market’, so it currently falls outside the regulation for the manufacture and supply of medicinal product Directive 2001/83/EC.

Oxygen 93 concentrator units are covered by the requirements for CE marking in accordance with the Medical Device Directive, (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices).

The specification of the oxygen manufactured using an oxygen 93 supply system is detailed in the European Pharmacopoeia monograph for oxygen 93, which specifies the oxygen content to be between 90% and 96% and gives appropriate limits and analysis methods of other possible contaminants during the production.

As the oxygen 93 is produced by adsorbing the nitrogen from ambient air, the major contaminant in oxygen 93 is argon, which can be present up to 5%.

When the oxygen 93% monograph was introduced it was stated that the benefits of PSA oxygen (oxygen 93 per cent) are to allow production and supply of oxygen at sites where access for cylinder and liquid oxygen supply is difficult or impossible. PSA concentrators are in use in a number of fields particularly by the military (field hospitals).

The quality of the gas is very much dependent upon the performance of the equipment that produces it.

At the time of preparation of this publication, oxygen 93 is not licensed under a marketing authorisation, thus it is not evaluated by regulatory authorities and thus it cannot be considered as “equivalent medicine” for the oxygen.

EIGA 2015

Descrizione Livello Dimensione Downloads
Allegato riservato Safe Design and Operation On Site Generation Oxygen 93 for Medical Use.pdf
EIGA 2015
291 kB 13

Tags: Chemicals EIGA

Articoli correlati

Ultimi archiviati Chemicals

Nota MdS 19 09 2022   Prime istruzioni operative Dlgs 134 2022
Set 23, 2022 46

Nota MdS 19.09.2022 / Prime istruzioni operative Dlgs 134/2022

Nota MdS 19.09.2022 / Prime istruzioni operative Dlgs 134/2022 ID 17679 | 23.09.2022 / Nota in allegato Nota Ministero della Salute del 19 Settembre 2022 Decreto legislativo 5 agosto 2022 n. 134, recante disposizioni in materia di sistema di identificazione e registrazione (I&R) degli operatori,… Leggi tutto
Set 21, 2022 56

Rettifica del regolamento (UE) 2022/1616 - 21.09.2022

Rettifica del regolamento (UE) 2022/1616 Rettifica del regolamento (UE) 2022/1616 della Commissione, del 15 settembre 2022, relativo ai materiali e agli oggetti di materia plastica riciclata destinati a venire a contatto con i prodotti alimentari e che abroga il regolamento (CE) n. 282/2008 GU L… Leggi tutto
Relazione certificazione LEA 2020 alimenti e veterinaria
Set 21, 2022 43

Relazione certificazione LEA 2020 alimenti e veterinaria

Relazione certificazione LEA 2020 alimenti e veterinaria A cura di Ministero della salute - Anno 2022 / Periodo di riferimento 2020 ... La valutazione complessiva dell'efficacia dei controlli ufficiali, tramite un pool di 103 indicatori quali-quantitativi, mostra un elevato livello generale di… Leggi tutto
REACH Authorisation List
Set 05, 2022 98

REACH Authorisation Decisions List | Last update 05.09.2022

REACH Authorisation Decisions List / Last update: 05.09.2022 REACH Authorisation Decisions List of authorisation decisions adopted on the basis of Article 64 of Regulation (EC) No 1907/2006 (REACH). The list also includes reference to related documentation concerning all applications for… Leggi tutto
How to use RAPID N
Ago 23, 2022 154

Guida utilizzo RAPID-N (Rapid Natech Risk Assessment Tool)

Guida utilizzo RAPID-N (Rapid Natech Risk Assessment Tool) JRC 2022 - Metodologia, modelli, informazioni tecniche e tutorialRAPID-N è un sistema basato sul web per l'analisi e la mappatura del rischio degli impatti dei pericoli naturali sui siti industriali, noto anche come rischio Natech. Il… Leggi tutto
Ago 15, 2022 114

Regolamento di esecuzione (UE) 2016/879

Regolamento di esecuzione (UE) 2016/879 Regolamento di esecuzione (UE) 2016/879 della Commissione, del 2 giugno 2016, che stabilisce, ai sensi del regolamento (UE) n. 517/2014 del Parlamento europeo e del Consiglio, modalità dettagliate relative alla dichiarazione di conformità al momento… Leggi tutto
TECHNI 1
Ago 14, 2022 195

Technical proposals for selected new fertilising materials under the Fertilising Products Regulation

Technical proposals for selected new fertilising materials under the Fertilising Products Regulation (Regulation (EU) 2019/1009) ID 17336 | 14.08.2022 Process and quality criteria, and assessment of environmental and market impacts for precipitated phosphate salts & derivates, thermal oxidation… Leggi tutto

Più letti Chemicals

Regolamento  CE  n  178 2002
Lug 22, 2022 68326

Regolamento (CE) N. 178/2002

Regolamento (CE) n. 178/2002 Regolamento (CE) n. 178/2002 del Parlamento europeo e del Consiglio del 28 gennaio 2002 che stabilisce i principi e i requisiti generali della legislazione alimentare, istituisce l'Autorità europea per la sicurezza alimentare e fissa procedure nel campo della sicurezza… Leggi tutto